The University of Chicago Header Logo

Connection

Daniel Shevrin to Steroid 17-alpha-Hydroxylase

Back to Details
This is a "connection" page, showing publications Daniel Shevrin has written about Steroid 17-alpha-Hydroxylase.
Daniel Shevrin
Connection Strength
0.121
Steroid 17-alpha-Hydroxylase
  1. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014 Mar 01; 20(5):1335-44.
    View in: PubMed
    Score: 0.121
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.